PURE Bioscience (OTCMKTS:PURE) Sees Significant Decline in Short Interest

PURE Bioscience (OTCMKTS:PURE) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 2,900 shares, a drop of 29.3% from the September 30th total of 4,100 shares. Based on an average daily volume of 45,400 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 45,400 shares, the short-interest ratio is presently 0.1 days.

PURE Bioscience Stock Performance

Shares of PURE stock traded down $0.00 during trading hours on Monday, hitting $0.07. 3,459 shares of the company were exchanged, compared to its average volume of 55,133. PURE Bioscience has a one year low of $0.05 and a one year high of $0.21. The business’s 50-day simple moving average is $0.08 and its two-hundred day simple moving average is $0.08. The stock has a market capitalization of $7.53 million, a price-to-earnings ratio of -1.68 and a beta of 0.41.

PURE Bioscience (OTCMKTS:PURE) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $1.71 million for the quarter.

About PURE Bioscience

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.